Share Email Print
cover

Proceedings Paper

Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity dependent on photoactivation
Author(s): G. Berkovitch; A. Nudelman; B. Ehenberg; A. Rephaeli; Z. Malik
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

New approaches to PDT using multifunctional 5-aminolevulinic acid (ALA) based prodrugs activating mutual routes of toxicity are described. We investigated the mutual anti-cancer activity of ALA prodrugs which upon metabolic hydrolysis by unspecific esterases release ALA, formaldehyde or acetaldehye and the histone deacetylase inhibitor (HDACI) butyric acid. The most potent prodrug in this study was butyryloxyethyl 5-amino-4-oxopentanoate (AN-233) that stimulated a rapid biosynthesis of protoporphyrin IX (PpIX) in human glioblastoma U-251 cells and generated an efficient photodynamic destruction. AN-233 induced a considerable high level of intracellular ROS in the cells following light irradiation, reduction of mitochondrial activity, dissipation of the mitochondrial membrane potential resulting in necrotic and apoptotic cell death. The main advantage of AN-233 over ALA stems from its ability to induce photodamage at a significantly lower dose than ALA.

Paper Details

Date Published: 13 July 2009
PDF: 9 pages
Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73800Z (13 July 2009); doi: 10.1117/12.822703
Show Author Affiliations
G. Berkovitch, Bar Ilan Univ. (Israel)
A. Nudelman, Bar Ilan Univ. (Israel)
B. Ehenberg, Bar Ilan Univ. (Israel)
A. Rephaeli, Tel-Aviv Univ. (Israel)
Z. Malik, Bar Ilan Univ. (Israel)


Published in SPIE Proceedings Vol. 7380:
Photodynamic Therapy: Back to the Future
David H. Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top